AMRX - Amneal Pharmaceuticals, Common Stock - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

AMRX is currently covered by 5 analysts with an average price target of $10.19. This is a potential upside of $2.13 (26.43%) from yesterday's end of day stock price of $8.06.

Amneal Pharmaceuticals, Common Stock's activity chart (see below) currently has 66 price targets and 58 ratings on display. The stock rating distribution of AMRX is 84.62% BUY and 15.38% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 60.74% with an average time for these price targets to be met of 278 days.

Highest price target for AMRX is $12, Lowest price target is $11, average price target is $9.8.

Most recent stock forecast was given by BALAJI PRASAD from BARCLAYS on 03-Mar-2025. First documented stock forecast 08-May-2018.

Best performing analysts who are covering AMRX - Amneal Pharmaceuticals, Common Stock:

John Boris Gregory Fraser Balaji Prasad David Risinger David Amsellem Nathan Rich Chris Schott Ami Fadia Randall Stanicky Gregg Gilbert

Currently out of the existing stock ratings of AMRX, 11 are a BUY (84.62%), 2 are a HOLD (15.38%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Balaji Prasad (BARCLAYS)

Buy

$11

$3.03 (38.02%)

$10

4 months 22 days ago
(03-Mar-2025)

7/9 (77.78%)

$2.24 (25.57%)

654

Please subscribe to see the analyst performance score

Chris Schott (JPMORGAN)

Hold

$12

$4.03 (50.56%)

5 months 1 days ago
(24-Feb-2025)

2/3 (66.67%)

$4.17 (53.26%)

Please subscribe to see the analyst performance score

David Amsellem (PIPER SANDLER)

Buy

$11

$3.03 (38.02%)

8 months 14 days ago
(11-Nov-2024)

7/9 (77.78%)

$1.8 (19.57%)

292

Please subscribe to see the analyst performance score

Nathan Rich (GOLDMAN SACHS)

Buy

$0.03 (0.38%)

$6.25

1 years 2 months 19 days ago
(06-May-2024)

6/6 (100%)

$1.35 (20.30%)

106

Please subscribe to see the analyst performance score

Gregory Fraser

Buy

$-0.97 (-12.17%)

1 years 8 months 17 days ago
(08-Nov-2023)

4/4 (100%)

$2.94 (72.41%)

150

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is AMRX (Amneal Pharmaceuticals, Common Stock) average time for price targets to be met?

On average it took 278 days on average for the stock forecasts to be realized with a an average price target met ratio 60.74

Which analyst has the current highest performing score on AMRX (Amneal Pharmaceuticals, Common Stock) with a proven track record?

JOHN BORIS

Which analyst has the most public recommendations on AMRX (Amneal Pharmaceuticals, Common Stock)?

John Boris has 7 price targets and 4 ratings on AMRX

Which analyst is the currently most bullish on AMRX (Amneal Pharmaceuticals, Common Stock)?

Chris Schott with highest potential upside - $4.03

Which analyst is the currently most reserved on AMRX (Amneal Pharmaceuticals, Common Stock)?

Gregory Fraser with lowest potential downside - -$0.97

Amneal Pharmaceuticals, Common Stock in the News

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

Amneal Pharmaceuticals LLC -Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), an American biopharmaceutical company, and Apiject Systems, Corp. (“Apiject”),...

3 Value Stocks in Hot Water

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out...